Keap1/Nrf2 pathway in kidney cancer:frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma by Fabrizio, Federico Pio et al.
  
 University of Groningen
Keap1/Nrf2 pathway in kidney cancer
Fabrizio, Federico Pio; Costantini, Manuela; Copetti, Massimiliano; la Torre, Annamaria;






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Fabrizio, F. P., Costantini, M., Copetti, M., la Torre, A., Sparaneo, A., Fontana, A., ... Fazio, V. M. (2017).
Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell
carcinoma. Oncotarget, 8(7), 11187-11198. https://doi.org/10.18632/oncotarget.14492
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Oncotarget11187www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/                 Oncotarget, 2017, Vol. 8, (No. 7), pp: 11187-11198
Keap1/Nrf2 pathway in kidney cancer: frequent methylation of 
KEAP1 gene promoter in clear renal cell carcinoma
Federico Pio Fabrizio1,*, Manuela Costantini2,5,4,*, Massimiliano Copetti3, Annamaria 
la Torre1, Angelo Sparaneo1, Andrea Fontana3, Luana Poeta4, Michele Gallucci5, 
Steno Sentinelli6, Paolo Graziano7, Paola Parente7, Vincenzo Pompeo5, Laura De 
Salvo6, Giuseppe Simone5, Rocco Papalia5, Francesco Picardo2, Teresa Balsamo1, 
Gerardo Paolo Flammia8, Domenico Trombetta1, Angela Pantalone2, Klaas Kok9, 
Ferronika Paranita9, Lucia Anna Muscarella1,*, Vito Michele Fazio1,2,*
1Laboratory of Oncology, IRCCS “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy
2Genetic and Clinic Pathology Unit, University Campus Bio-Medico of Rome, Rome, Italy
3Unit of Biostatistics, IRCCS “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy
4Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy
5Department of Urology, Regina Elena National Cancer Institute, Rome, Ital
6Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy
7Unit of Pathology, IRCCS “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy
8UOC of Urology, Campus Bio-Medico University Hospital, Rome, Italy
9Department of Genetics, University of Groningen, University Medical Center Groningen, The Netherlands
*These authors equally contributed to this work
Correspondence to: Lucia Anna Muscarella, email: l.muscarella@operapadrepio.it
Keywords: ccRCC, KEAP1, methylation, epigenetic biomarker, outcome
Received: June 13, 2016    Accepted: December 27, 2016    Published: January 04, 2017
ABSTRACT
The Keap1/Nrf2 pathway is a master regulator of the cellular redox state through 
the induction of several antioxidant defence genes implicated in chemotherapeutic 
drugs resistance of tumor cells. An increasing body of evidence supports a key role 
for Keap1/Nrf2 pathway in kidney diseases and renal cell carcinoma (RCC), but data 
concerning the molecular basis and the clinical effect of its deregulation remain 
incomplete.
Here we present a molecular profiling of the KEAP1 and NFE2L2 genes in five 
different Renal Cell Carcinoma histotypes by analysing 89 tumor/normal paired tissues 
(clear cell Renal Carcinoma, ccRCCs; Oncocytomas; Papillary Renal Cell Carcinoma 
Type 1, PRCC1; Papillary Renal Cell Carcinoma Type 2, PRCC2; and Chromophobe Cell 
Carcinoma).
A tumor-specific DNA methylation of the KEAP1 gene promoter region was found 
as a specific feature of the ccRCC subtype (18/37, 48.6%) and a direct correlation 
with mRNA levels was confirmed by in vitro 5-azacytidine treatment. Analysis of an 
independent data set of 481 ccRCC and 265 PRCC tumors corroborates our results 
and multivariate analysis reveals a significant correlation among ccRCCs epigenetic 
KEAP1 silencing and staging, grading and overall survival.
Our molecular results show for the the first time the epigenetic silencing of 
KEAP1 promoter as the leading mechanism for modulation of KEAP1 expression in 
ccRCCs and corroborate the driver role of Keap1/Nrf2 axis deregulation with potential 




Renal cell carcinoma is the most common 
malignant neoplasm arising in the kidney and comprises 
an heterogeneous group of tumors. Various histotypes 
of RCC have come to be defined on the basis of their 
histologic appearance, the presence of distinct driver 
mutations, varying clinical course, and different responses 
to therapy [1, 2]. On the basis of morphology RCCs are 
classified into clear cell carcinomas, papillary tumors, 
chromophobic tumors, oncocytomas, and collecting duct 
tumors. Clear cell Renal Cell Carcinoma (ccRCC) are the 
most common ones, with a frequency of 70–80% of all 
renal cancers. At time of diagnosis as many as one-third 
of the ccRCC patients may have a metastatic disease and 
about half of the patients will have a recurrence.
Papillary RCC, which accounts for 15% of RCCs 
encompasses type I papillary RCC (PRCC1) and type 
II papillary RCC (PRCC2). Although inhibition of the 
specific cellular signaling pathways has led to some 
clinical benefits, the effect is marginal and the prognosis 
remains poor for patients with advanced disease.
The premise that RCC histotypes might represent 
distinct diseases is underscored by multilevel genomics-
based taxonomy studies. Moreover, different DNA 
methylation patterns have been characterized both across 
and within the histology-based subgroups, revealing 
different RCC molecular subtypes, some of these in 
association with a more aggressive behaviour [3]. 
In both clear cell and papillary histotypes the 
Keap1/Nrf2 pathway, the KEAP1 (Kelch-like erythroid-
derived Cap-n-Collar Homology (ECH)-associated 
protein-1, NFE2L2 (Nuclear factor (erythroid-derived 
2)-like2, and CUL3 (Cullin 3) were recently identified 
as probable drivers. This finding was consistent with the 
current knowledge that RCC belongs to the type of tumors 
in which the Nrf2 pathway was shown to be constitutively 
activated mainly by the loss of Keap1 functions that 
lead to Nrf2 nuclear accumulation and enhances the 
transcription of Phase II enzymes [4]. The induced 
activation of metabolizing enzymes confers to neoplastic 
cells resistance to radio- and chemotherapies with growth 
and survival advantages during their transformation and 
progression [5–6]. Moreover, the transcription factor 
Nrf2 plays an important role from acute kidney injury 
to chronic kidney disease and cancer and transcriptional 
activity of Nrf2 has been inversely correlated with FH 
enzyme activity, which is loss in PRCC2 [7–8]. 
Genetic alterations of Keap1/Nrf2 axis were 
described with a variable incidence in RCC, more 
frequently in PRCC2 [3, 9]. Genetic alterations of the 
Keap1/Nrf2 pathway were reported in a very small fraction 
of ccRCC patients. However, several studies demonstrated 
a general high impact of Nrf2 dysfunction in renal cell 
carcinoma, suggesting that the deregulation of the Keap1 
may play a role in carcinogenesis process histotypes 
beside the presence of genomic alterations [10, 11]. We 
have previously reported that epigenetic modification by 
promoter methylation is a main mechanism of regulation 
of KEAP1 gene expression in Non Small Cell Lung 
Cancer, malignant gliomas, breast cancer and that it was 
associated with worst progression free survival [12–16]. 
Since the role of DNA methylation and genes 
epigenetically altered in RCC have been an active area 
of research over the past decade, the main purpose of 
this study is to investigate the contribution of epigenetic 
deregulation of the KEAP1 gene in different histotypes of 
renal cell carcinomas. 
To address this issue, the analyses were stratified 
for the main five histological subtypes of renal cancer: 37 
ccRCCs, 15 PRCC1s, 13 PRCC2s, 14 Oncocytomas and 
13 Chromophobe Renal Cancers.
A clear association of KEAP1 promoter methylation 
and the ccRCC histology was found in a training set of 
37 cases with an incidence of 49%. A direct effect on 
Keap1 mRNA levels was demonstrated by in vitro 
experiments on a set of  four ccRCC cell lines. The 
specific correlation between the KEAP1 methylation 
and the Clear Cell histology was also validated by using 
two independent datasets of 481 ccRCC and 264 PRCC 
affected patients from The Cancer  Genome Atlas (TCGA) 
portal, showing a significant correlation with the ccRCCs’ 
staging, grading and overall survival.
DNA-based assays are often more robust than 
RNA-based assays, and genes inactivated by promoter 
hypermethylation may provide a better target for 
molecular screening strategies to identify targeted 
therapies. Since the histologic appearance is considered 
the primary determinant in the classification of Renal 
Cancer [17], the discovery of specific variations in 
methylation profiles could further help to stratify the clear 
cell renal carcinoma subtype from others [3]. Moreover, 
our findings of KEAP1 hypermethylation provide the first 
indication that this epigenetic mechanism is important also 
in the regulation of KEAP1 expression in an aggressive 
renal cancer histotype and could represents an additional 
and attractive diagnostic and prognostic biomarker.
RESULTS
Patients and treatment
Patients’ clinico-pathological features of all the 
Renal Cell Carcinoma histotypes analyzed into the study 
are summarized in Table 1. Overall, the series included 
89 patients grouped in: 37 ccRCCs (41.6%), 15 PRCC1s 
(16.9%), 13 PRCC2s (11.2), 10 Chromophobe Renal 
Cell Carcinomas (14.6%) and 14 Oncocytomas (15.7%), 
respectively. The mean patient’s age at the time of 
diagnosis was 63.0 ± 13.5 (yy ± SD) with a range from 
23 to 86 years. More than half of the patients were men 
(68.6%) versus 31.4% of women. All patients underwent 
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curative surgery and all malignant lesions were subjected to 
staging according to the TNM system (2009 classification): 
we found 38 T1 cases (50.7%), 13 T2 cases (17.3%), 21 
T3 cases (28%) and 3 T4 cases (4%). According to the 
Table 1: Clinical, tumor stages and histological features of RCC affected patients enrolled for the 
study (n = 89) 
Characteristics n (%) ccRCC
Age at the surgery (median (IQR)) 63 (23–86) 56 (48–70)
Sex 89 37
M 61 (68.6) 28 (76)
F 28 (31.4) 9 (24)
Histology 89 37
Clear cell 37 (41.6)
Chromophobe 13 (14.6)
Papillary tipe 1 15 (16.9)
Papillary type 2 10 (11.2)
Oncocytoma 14 (15.7)
Tumour Stage (excluded oncocytomas) 75 (84.2)
1a 14 (18,7) 4 (11)
1b 24 (32) 8 (22)
2a 9 (12)
2b 4 (5.3) 10 (27)
3a 15 (20) 5 (13)
3b 6 (8) 3 (8)
4 3 (4) 0 (0)
Lymph nodes stage  (excluded oncocytomas) 75 30
N0 20 (26.6) 16 (43)
N1 1 (1.4) 0 (0)
N2 7 (9.3) 4 (11)
Nx 47 (62.7) 17 (46)
Clinical Metastasis stage 89 37
M0 76 (85.3) 16 (43)
M1 13 (14.7) 21 (57)
Fuhrman Grading (only ccRCC) 37
Grade I 1(2.7)
Grade II 5 (13.5)
Grade III 19 (51.4)
Grade IV 12 (32.4)
PFS 89 37
Yes 26 (29.2) 16 (43)
No 63 (70.8) 21 (57)
OS (excluded oncocytomas) 75 37
Death 7 (9.3) 3 (8)
Alive 68 (90.6) 34 (92)
Data are reported as median (IQR) for continuous variables and as frequencies and percentages for categorical variables; 
OS, Overall Survival.
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CAP guideline (College of American Pathologist) the 
Fuhrman grading was attributed only to ccRCC, showing 
a heterogeneous spectrum of aggressiveness: 1 case G1 
(2.7%), 5 G2 (13.5%), 19 G3 (51.4%) and 12 G4 (32.4%).
Excluding benign lesions as oncocytomas, the lymph 
node involvement at the diagnosis was found only in 
8 cases (N1 and N2 patients), whereas 67 patients didn’t 
show lymphnode metastasis (Nx and N0 cases). During 
follow-up, 33 patients (37%) showed a relapse with 7 cases 
of local/ renal recurrence (7.8%) and 26 cases (29.2%) of 
distant metastasis (target organs: lungs, bone, liver and brain). 
The mean and median follow-up time was respectively 31.2 
and  24.5 months with a range of 1–108 months. 
During follow-up, 9 patients (10.1%) died of RCC, 
whereas 80 (89.9%) patients were still alive, with 92.2% 
survived at last follow-up. An Overall Survival equal 
to 90.6% was observed. Clinical characteristics of our 
series are in line with the just published data [18–19]. The 
number of cases for each histotype was chosen similar to 
perform an effective comparison. The number of ccRCCs 
was larger than the others since the inclusion of the two 
different metastatic and non-metastatic groups.  
KEAP1 promoter methylation profile in renal 
carcinoma tissues
The KEAP1 methylation level was firstly evaluated 
on DNA obtained from a total of 89 RCC tissues, 70 paired 
normal renal tissues distant from the tumors (NRDT) and 
10 normal renal tissues from patients affected by urothelial 
carcinoma (NR), (Supplementary Figures 2 and 3).The 
median values and Inter Quartile Ranges (IQR) for KEAP1/
ACTB ratios were 0.0 (0–0) for NR, 0 (0.000–0.329), for 
NRDT paired with ccRCC, and 0.611 (0.000–10.210) 
for ccRCC tumor tissues, (Figure 1). The discriminatory 
power of the KEAP1 QMSP assay was assessed by 
estimating the area under the ROC curve using paired 
normal renal tissues distant from tumor and ccRCCs. The 
AUC value was 0.68, with an optimal cut-off value of 1.56, 
a sensitivity of 49% and a specificity of 87%. In ccRCC 
methylation was detected in 18 out of 37 cases (48.6%), 
(Supplementary Figure 4). No statistically significant 
differences in methylation levels was detected between the 
NR and NRDT group. However, statistically significant 
differences were found when the NRDT and ccRCC group 
were compared (p = 0.0054; Wilcoxon Signed rank Test). 
No significant differences were found between NRDT and 
the other RCC histotypes.
In order to independently validate the specific 
correlation of data obtained to the ccRCC histotype, the 
KEAP1 methylation and the functional effect of KEAP1 
promoter methylation on its expression was analyzed in two 
independent datasets of 481 ccRCC and 265 PRCCs cancer 
samples available from The Cancer Genome Atlas portal 
(TCGA), (for ccRCC cohort characteristics see additional 
Supplementary Table 2). The KEAP1 gene has a 1.2 kb 
CpG island ( chr19:10613047-10614280, hg19/GRCh37) 
extending from the promoter region to intron 1, that is 
recognized by seven probes (denoted as 1 to 7) present on 
the Illumina Human-Methylation450 Bead Chip, all near 
the transcription start site of the KEAP1 gene (Figure 2A). 
A highly significant inverse correlation of aberrant 
KEAP1 promoter methylation and KEAP1 mRNA 
expression was found in both ccRCC and PRCC samples 
Figure 1: Boxplots of KEAP1 promoter methylation levels in Normal Renal tissues (NR), and different renal tumor 
histologies included into this study,  paired with normal renal parenchyma distant from tumor.  Methylation levels are 
expressed as the (KEAP1/ACTB)*1,000. The boxes mark the interquartile range, (interval between the 25th and 75th percentile). ccRCC, 
clear cell Renal Cell Cancer; PRCC1, Papillary Renal Cell Carcinoma Type 1; PRCC2, Papillary Renal Cell Carcinoma Type 2.
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showing a methylation value > 0,10 (Figure 2B). However, 
a methylation value > 0,10 was observed only in 3% 
(7 out of 265) of PRCCs, thus confirming results obtained 
on our small cohort of an inconsistent contribution of the 
KEAP1 promoter epigenetic silencing in this histology, 
(Supplementary Figure 5).
Association of KEAP1 methylation with clinical 
parameters in ccRCCs
We finally examined the correlation between the 
KEAP1 QMSP methylation level and patients’ clinical data. 
Specifically, we did not find any significant correlation 
between the KEAP1 methylation level and lymph node 
status, or grading. Moreover, there was no significant 
association between KEAP1 methylation and disease free 
survival, local recurrence or overall survival. Taking into 
account the few samples available, the same correlation 
analysis was then performed on the TCGA ccRCC dataset. 
For each CpG site of the KEAP1 promoter gene region, 
the samples were stratified according KEAP1 methylation 
median level to estimate the association with clinical 
parameters as independent prognostic molecular marker. 
Relevant results were summarized in Table 2: CpG 
methylation at exon 1 and intron 1 revealed significant 
association with Overall Survival (OS), grading, staging 
and tumor dimension. No association was found with age 
and sex, lymphonodes count and metastasis.
Restoration of KEAP1 expression correlated 
with demethylation by 5-aza-dC treatment
The methylation status of the four ccRCC cell lines 
FG-2, FW, 5 and EW was assessed. QMSP analysis showed 
a variable methylation level of KEAP1 (Figure 3). To verify 
whether the repression of KEAP1 expression was correlated 
with CpG methylation in the gene promoter, we examined the 
variation of KEAP1 mRNA level in the four cell lines before 
and during treatment with 5-aza-dC (Figure 4A, 4C, 4E). By 
real-time quantitative PCR analysis a progressive increase 
in the KEAP1 transcript abundance was observed after 
48 h (p < 0.0001) and was shown to correlate in ccRCC FW, 
ccRCC FG-2, ccRCC 5 with a decreased KEAP1 promoter 
methylation at 48 h (p < 0.001 respectively), (Figure 4B, 
4D, 4F). Keap1 expression did not reveal any significant 
variation in the ccRCC EW.
Figure 2: The 450 K methylation array data from the TCGA demonstrates that methylation of the KEAP1 promoter 
region is a hallmark in ccRCC. (A) The KEAP1 gene structure, including its transcription start site (TSS), exons (black boxes) and 
introns (lines), a 1.2-kb CpG island of the KEAP1 gene (green  bar) and the location of  the  probes present on the 450 K array (short black 
numbered lines, denoted as probes 1-7 for target ID cg06911149 and cg02428100 located into the exon 1 and cg03890664, cg15204119, 
cg15676203, cg26500801, cg26988016 located into the intron 1). (B) Inverse correlation of KEAP1 mRNA expression with the DNA 
methylation status in ccRCC. p: Spearman correlation coefficient.  
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KEAP1 deregulation is not caused by somatic 
alterations in the DGR domain of KEAP1 or 
Nhe2 domain of NFE2L2 in renal cell carcinoma
An alternative mechanism to achieve the deregulation 
of KEAP1 would be the occurrence of somatic mutations in 
our RCC samples. To exclude this possibility we analysed 
20 ccRCCs (11 KEAP1 methylated and 9 unmethylated 
samples) and 10 PRCC2 tumors for somatic alterations 
in the most frequently mutated coding regions of the 
KEAP1 and NFE2L2 genes. Specifically, we search for 
molecular lesions in the KEAP1 Double Glycin Region 
(DGR) domain, which contains binding sites for Nrf2, 
Bcl2, Pgam5 and Ikkβ proteins. We also check for somatic 
alterations in the Nhe2 domain of the NFE2L2. This analysis 
did not reveal any sequence variations that would likely 
result in a functional alteration in Keap1 or Nrf2 proteins, 
(Supplementary Table 2).
Table 2: Prognostic association of CpGs located into the KEAP1 promoter region with clinical





cg06911149 exon 1 0.01 0.0107 0.0005 0.0003 −0.20, <.0001
cg02428100 exon 1 0.426 0.0287 0.027 0.008 −0.24, <.0001
cg03890664 intron 1 0.139 0.9084 0.1388 0.2529 −0.10, 0,0165
cg15204119 intron 1 0.002 0.0019 < 00001 0.0015 −0.25, <.0001
cg15676203 intron 1 0.009 0.0037 0.0007 0.0005 −0.19, <.0001
cg26500801 intron 1 0.013 0.0549 0.0126 0.0183 −0.25, <.0001
cg26988016 intron 1 < 0.001 0.5512 0.0399 0.0147 −0.21, <.0001
characteristics and Overall Survival.
Figure 3: KEAP1 promoter methylation levels in four ccRCC cell lines (5, EW, FG-2, FW) detected by using quantitative 
methylation real-time PCR. Values were reported as the KEAP1/ACTB ratio*1000. Error bars indicate the standard error of three 
different experiments.
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KEAP1 promoter methylation and Keap1 
immunostaining
To assess the potential correlation between the Keap1 
protein levels in ccRCCs and the epigenetic silencing of 
the KEAP1 gene, 15 ccRCC tumor cases showing KEAP1 
promoter methylation and 14 tumors without methylation 
were analysed by immunohistochemical analysis.
A semi-quantitative scoring system based on 
staining intensity and percentage of positive neoplastic 
cells to evaluate Keap1 immunoreactivity was applied. 
All the areas of the tissue section were evaluated for 
Keap1 protein expression. Cases were scored as positive 
if independently evaluated by two pathologists (PG 
and PP). Keap1 immunoreactivity was observed in the 
cytoplasm of tumor cells. Representative images of 
Figure 4: Changes in KEAP1 mRNA transcript levels in the (A) ccRCC-FW, (C) ccRCC 5, (E) ccRCC FG-2 cell lines by quantitative 
real-time RT-PCR before (CTRL) and after treatment with 5 µm of 5-azacytidine at 48 hours (AZA 48 h). Error bars indicate the standard 
deviation of three different experiments. Changes in KEAP1 promoter methylation levels in the (B) ccRCC FW, (D) ccRCC 5, (F) ccRCC 
FG-2 cell lines by quantitative methylation real-time PCR before (CTRL) and after treatment with 5 µm of 5-azacytidine at 48 hours (AZA 
48 h). Error bars indicate the standard deviation of three different experiments. **p < 0.01, ***p < 0.001.
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immunohistochemical staining are shown in Figure 5. A 
no statistically significant difference was observed.
DISCUSSION
A growing amount of evidence suggest that an 
increased activity of Nrf2 due to NFE2L2 or KEAP1 
mutations may play a pivotal role in the pathogenesis of 
many solid tumors and recently emerged as one of the main 
pathways implicated in Renal Carcinoma [13, 20–22]. Of 
note, deregulation of Keap1/Nrf2 pathway was highlighted in 
the Papillary Type 2 subtype of renal cancer as a consequence 
of an abnormal fumarate accumulation in congenital fumarate 
hydratase deficiency [13, 20] which predisposes to PRCC2. 
Somatic mutations in NFE2L2 and CUL3 genes 
were also frequently reported in sporadic cases with 
PRCC2, but less frequently for the clear-cell subtypes 
of RCC. Somatic mutations in NFE2L2 and CUL3 genes 
were also reported more frequently for sporadic cases with 
PRCC2 than for the clear-cell subtypes of RCC [21, 23].
This could be explained taking into account the 
heterogeneity features of renal cancer and more importantly 
by an existing alternative epigenetic mechanism to regulate 
Keap1-Nrf2 signalling.  KEAP1 promoter epigenetic 
silencing as just reported in cancers as well as in the other 
diseases with a clear association with tumors having a low 
incidence of somatic mutations [22, 24].
Since no data are available regarding the contribution 
of KEAP1 hypermethylation in renal cancer, we decided 
to investigate this epigenetic mechanism of silencing 
by performing a comprehensive genetic and epigenetic 
analysis in 89 surgical resected RCCs. As main result, an 
aberrant promoter KEAP1 methylation was identified in 
the ccRCC subset with a frequency of 49%. The strong 
correlations with this specific histotype was then confirmed 
by the revision of the TCGA data for two different 
cohorts of 481 ccRCCs and 265 PRCCs. Moreover, we 
demonstrated that the methylation of the KEAP1 CpG 
island represents a critical mechanism regulating the 
transcription levels of the KEAP1 gene by showing a 
statistical significant inverse Pearson Correlation between 
KEAP1 methylation and transcript levels. Further, these 
data are corroborated by the fact that pharmacological 
5-Aza treatment is able to restore the expression of Keap1 
in 3 out of 4 different ccRCC cell lines.
Methylation levels did not correlate with the 
Keap1 protein expression assessed in 29 ccRCC tumors 
by IHC analysis. The reasons for this lack of association 
might be due to several reasons. First, there is a lack of a 
consistently defined cut-off value for the semiquantitative 
immunohistochemical scoring and to detection limit [25]. 
Moreover, ccRCCs are heterogeneous/multifocal tumours 
and intra-tumoral heterogeneity could involve epigenetic 
changes similar to genetic and genomic events [26–27]. 
QMSP is a highly sensitive methodology and methylation 
signals may be obtained even if cells that carry KEAP1 
promoter methylation represent a small proportion 
among the majority of cells with unmethylated promoter. 
Conversely, IHC may not be able to detect small clusters of 
cells that have lost protein expression.”
No genetic abnormalities were identified by 
analysing the DNA obtained from a subset of 20 ccRCCs 
and 14 PRCC2s. This result is in line with public data 
on the somatic mutation frequency of KEAP1 in RCC. 
The COSMIC database has KEAP1 sequence data 
on 953 cases of ccRCC of which only 8 had a non-
synonymous KEAP1 mutation (0.8%) and 1/875 had a 
non-synonymous  NFE2L2 mutation (0.1%). Moreover, 
in the TCGA analysed dataset, only 2 out of 446 ccRCCs 
had a mutations (0.5%). In papillary RCCs, 8 out of 183 
non-synonymous NFE2L2 mutations are described (4%), 
[28]. This result partially confirms the previous available 
Figure 5: Keap1 protein expression by immunohistochemical analysis. (A–B) Microphotographs are from a ccRCC sample 
negative for KEAP1 promoter methylation. (A) Original magnification X9. Scale bar 110 µm; (B) Original magnification X25. Scale bar 
40 µm. Tissue-associated macrophages are positive for Keap1 staining and are used as internal positive controls. (C–D) Weak staining in 
one ccRCC case with KEAP1 promoter methylation. (C) Original magnification X9. Scale bar 110 µm; (D) Original magnification X25. 
Scale bar 40 µm. Tissue-associated macrophages are positive for Keap1 staining and are used as internal positive controls.
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published data that reported a low rate of inactivating 
mutations of CUL3 or activating mutations of NFE2L2 in 
sporadic PRCC2. 
Deregulation of the Nrf2/Keap1 system has been 
linked to patient’s outcome and to resistance to a variety 
of anticancer drugs, due to the key role of Nrf2 in 
modulating the expression of phase II drug metabolism 
enzymes and phase III drug transporters [17]. In patients 
affected by solid tumors, a nuclear Nrf2 accumulation in 
combination with a low or absent Keap1 expression was 
associated with poor outcome. However, this was not 
well investigated in Renal Cancer. In our study follow up 
data were available for all 37 ccRCC cases. No evidence 
of a statistical significant correlation with the risk to 
progress was observed for patients bearing epigenetic 
abnormalities. This may be mainly due to the statistical 
power of the small sample cohort. Therefore, we extended 
our studies by analysing 450K methylation array data for 
the CpG promoter of KEAP1 for an independent cohort 
of 481 ccRCC patients with available clinic-pathological 
data. A clear association was observed between the 
hypermethylation of CpGs located in the KEAP1 promoter 
and an increased ccRCC tumor grading and staging, 
further supporting their biological relevance. Furthermore, 
the data analysis suggests that KEAP1 hypermethylation is 
able to predict patients’ survival. An increased methylation 
level of 5/7 CpGs was strongly associated with worse OS 
in ccRCCs.
Our study reports for the first time the 
epigenetic modulation of KEAP1 by CpGs promoter 
hypermethylation as the leading mechanism of KEAP1 
deregulation in ccRCC and together with recently 
published data on PRCC2, corroborate the hypothesis 
of a driver role of the Keap1/Nrf2 pathway in the 
ccRCCs subtypes with a specific epigenetic deregulation 
mechanism. In line with data from previous molecular 
studies, this epigenetic finding represents a new disease 
molecular marker for a specific subtype of RCC. An 
important avenue of future work will be to complement 
this epigenetic biomarker to existing renal cancer genetic 
biomarkers to assess their importance from the standpoint 
of therapy and clarify their potential for application 
in the clinical setting. At the same time, based on the 
high frequency of tumors displaying aberrant Nrf2 
activation, Nrf2 should be regarded as an important new 
pharmacological target [29, 30].
MATERIALS AND METHODS
Cell lines
ccRCC FG-2, ccRCC FW, ccRCC 5 and ccRCC EW 
clear renal cancer cell lines were obtained in collaboration 
with the UMCG, Department of Genetics, Groningen, 
the Netherland (Dr. Klaas Kok, PhD) and were cultivated 
in RPMI 1640 medium, supplemented with 10% FBS. 
DNA was extracted from each cell line by using the 
standard procedure with Phenol-Chloroform. RNA 
was extracted using Trizol reagent (Life Technologies) 
in according to the manufacturer’s instructions. DNA 
and RNA concentrations were estimated by NanoDrop 
Spectrophotometer ND-1000 (Thermo Scientific).
Patients and tissue samples
The patients’ clinical and pathological data including 
pathological TNM staging,  site of the lesion, grading, age, 
gender, and follow-up data were collected and are shown 
in Table 1. 
Renal cancer tissues samples were obtained as 
Formalin Fixed Paraffin Embedded (FFPE) specimens from 
89 patients surgically treated in the Department of Urology 
at the “Regina Elena” National Cancer Institute of Rome. 
All tissue specimens showing features of Clear Renal 
Cell Carcinoma (ccRCC, n = 37), Type I Papillary Renal 
Cell Carcinoma (PRCC1, n = 15), Type II Papillary 
Renal Cell Carcinoma (PRCC2, n = 13), Oncocytoma 
(n = 14) and Chromophobe Renal Cell Carcinoma 
(n = 13), attending the Outpatient Clinic of the Department 
of Urology or undergoing to curative surgical treatment 
during the period 2003–2013. Wherever possible, all 
available paired histologically confirmed normal renal 
tissues distant from tumor (NRDT, n = 70) and normal renal 
tissue samples from urothelial tumor patients (NR, n = 10) 
were collected. All human materials used in the study were 
obtained in compliance with guidelines of the Local Ethical 
Committee. 
After excision, tissues were collected in 10% 
formalin and embedded in paraffin for histopathological 
and immunohistochemical analysis. Tumor samples with 
at least 70% cancer cells were eligible for direct genetic 
and epigenetic analyses.  Cases showing tumor cellularity 
lower than 70% were microdissected for enrichment of 
neoplastic cell content.
DNA extraction
Sections, 3-μm-thick, were cut from FFPE tissue 
blocks and subjected to Hematoxilyn and Eosin (H&E) 
staining to verify tumor cellularity. Under light microscope, 
12-μm-thick sections of tumor specimens were then 
carefully dissected to enrich for areas that contained tumor 
cells. DNA was subsequently extracted from the paraffin-
embedded sections as previously described [31]. DNA 
concentrations were measured by using Thermo Scientific 
NanoDrop™ 1000 Spectrophotometer (Thermo Scientific).
Mutation analysis
DNA obtained from 20 ccRCC and 10 PRCC2 tissues 
was analysed by fluorescence-based direct sequencing of 
the entire KEAP1 gene region encoding the DGR (Double 
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Glycine Repeat) domain of the Keap1 protein and exon 
2 of the NFE2LE gene, encoding  the Nhe2 domain 
(Supplementary Table 3). Amplification reactions were 
performed by using the Gene Amp PCR System 9700 
Thermal cycler (Applied Biosystem, Foster City, CA), 
in a final reaction volume of 25 µl containing 100 ng of 
genomic DNA template, 0.25 nM dNTPs, 20 pmol of 
each primers, 1U HotMaster Taq polymerase (Eppendorf 
AG, Hamburg, Germany), in 10X Hot Master Taq Buffer 
with magnesium and sterile distilled water. PCR cycling 
conditions include an initial denaturation step at 94°C for 
2 min, followed by 35 cycles of 94°C for 30 sec, annealing 
for 30 sec, extension at 72°C for 30 sec and ending with 
a final elongation step at 72°C for 7 min. PCR products 
were purified using GFX PCR DNA and the Gel Band 
Purification Kit (GE Healthcare, Buckinghamshire, UK) 
and sequenced by using the Big Dye Terminator Ready 
Reaction mix v. 1.1 on an ABI 3100 sequence detection 
system with the Sequencing Analysis software v.3.7 
(Applied Biosystems). 
Bisulfite conversion of DNA and quantitative 
methylation specific PCR analysis (QMSP) 
One microgram of DNA extracted from cell lines and 
tissue samples was subjected to bisulfite treatment and DNA 
purification using the Epitect Bisulphite kit (Qiagen Sci, MD, 
USA) according to manufacturer’s instruction. Bisulfite-
modified DNA was used as template for Quantitative 
Methylation Specific PCR (qMS-PCR) to detect converted 
DNA. Primer/probe sets for the KEAP1 promoter region 
and for the unmethylated promoter region of the ACTB as 
reference gene were previously described and are reported 
in Supplementary Table 1 [12]. Calibration curves for both 
target and reference genes were constructed using serial 
dilutions (90–0.009 ng) of commercially available fully 
methylated DNA (CpGenome Universal Methylated DNA, 
Millipore, Chemicon, cat#S7821). Amplification reactions 
were carried out in triplicate in 384-well plates and in a 
volume of 10 mL that contained 50 ng of bisulfite-modified 
DNA on a ABI PRISM 7900 Sequence detection system 
and were analysed by SDS 2.1.1 software (Thermo Fisher 
Inc., Applied Biosystems division). Each plate included 
calibration curves for the ACTB and KEAP1 genes, patients’ 
DNA samples, a positive control CpGenome Universal 
Methylated DNA, and multiple water blanks (Supplementary 
Figure 1). The Cp (cross point) values of each QMSP 
reaction were calculated using the second derivative 
maximum method. The qMS-PCR standard curves of 
the KEAP1 and ACTB genes for the normalization of the 
input DNA were established with CpGenome Universal 
Methylated DNA. Methylation levels were finally calculated 
as the ratio of KEAP1 to ACTB and then multiplied by 1000 
for easier tabulation (average value of triplicates of Target 
Gene/average value of triplicates of ACTB× 1000).
In vitro 5-Aza-2′-deoxycytidine (5-aza-dC) 
treatment
FG-2, FW, 5 and EW ccRCC cell lines were seeded 
in a 6 well dish. The 5-aza-2′-deoxycytidine (DAC), 
an inhibitor of DNA methyltransferase, was added in 
a concentration of 5 µM (Sigma-Aldrich) with fresh 
medium for 24 h and 48 h. At both time points (24 h and 
48 h) cells were harvested for DNA and  RNA isolation to 
interrogate the effects of induced DNA demethylation and 
analyse the KEAP1 expression levels.
Quantification of the KEAP1 expression by 
real-time PCR
PCR fragments for KEAP1 and RPLPO were 
amplified by the Taqman assay listed in Supplementary 
Table 1, and were cloned into the StrataCloneTM PCR 
Cloning Vector pSC-A (Stratagene, Milan, Italy). Mini-
prep cultures were grown in 5 ml of LB-Ampicillin broth. 
Plasmid DNA from the selected transformed cells was 
isolated using the QIAprep® Spin Miniprep Kit (Qiagen) 
Five plasmid dilutions in the range of 1 × 106 copies to 
1 × 102 copies were used to construct the standard curves 
for real-time PCR.
First strand cDNA synthesis from 1 µg of total 
RNA extracted from renal cell lines was carried out 
with SuperScript III First-Strand Synthesis (Thermo 
Fisher, Invitrogen Division, Carlsbad, CA, USA) using 
a gene expression amplification mixture containing 
2.5 × TaqMan® Universal PCR Master Mix (Thermo 
Fisher, Life Technologies division), 250 nM of TaqMan™ 
Gene Expression Assay with TaqMan probe and 1 μl of 
template cDNA or plasmid product (serial dilutions), (Table 
1). Reactions were run on ABIPRISM 7900HT Sequence 
Detection System (Thermo Fisher, Life Technologies 
division). Protocol conditions were as follows: 10 min at 
95°C, 40 cycles at 95°C for 15 s and 60°C for 60 s. Each 
assay was carried out in triplicate and the transcription 
level was normalized using RPLPO as reference gene. 
Calibration curves for the KEAP1 and PRLPO genes 
(used as calculation method) were constructed and sample 
concentration was calculated using the plasmid standard 
curve, resulting in plasmid concentrations expressed as 
copy number of corresponding standard molecules. The 
relative sample amount was expressed as ratio marker 
([KEAP1/RPLPO]*1000 for an easier tabulation).
Immunohistochemistry (IHC)
Formalin fixed paraffin-embedded sections (3 µm) 
of 29 ccRCCs were selected for IHC analysis and collected 
on polarized slides. The sections were deparaffinised in 
xylene, hydrated in gradient alcohol, and warmed in Tris-
EDTA buffer (0.01 M, pH = 9.0) for antigen retrieval at 
Oncotarget11197www.impactjournals.com/oncotarget
98°C. The sections were then incubated with hydrogen 
peroxide (0.3% v/v) in methanol for 5 min to quench 
the endogenous peroxidase activity. Thereafter, the 
slides were incubated with rabbit polyclonal anti-Keap1 
antibody (AP-20503, Proteintech, Chicago, USA) for 
60 min at RT. The primary antibody was detected by using 
commercially available detection kit (EnVisionTMFLEX+, 
Dako, Glostrup, Denmark) following the manufacturer’s 
protocol and diaminobenzidine as chromogen.
Slides were washed with Tris-buffered saline (TBS, 
0.1 M, pH = 7.4), 3–5 times after each step. Finally, the 
sections were counterstained with Mayer’s hematoxylin 
and mounted with Biomount (BIO-OPTICA, Milan, Italy). 
In the negative control tissue sections, the primary antibody 
was replaced by isotype specific non-immune rabbit IgG. 
Tissue sections from colon cancer were used as a positive 
control for Keap1expression.The sections were evaluated 
by light microscopic examination on Olympus BX51 
microscope.
Each slide was evaluated for Keap1 immunostaining 
by using a semi-quantitative scoring system combining 
staining intensity and the percentage of positive neoplastic 
cells.
Immunoreactivity was assessed in all the areas of the 
tissue section. Keap1 protein expression, independently 
evaluated by two Pathologists (PG and PP) was scored 
as positive if cytoplasm reactivity was observed in 
tumor cells. The semi-quantitative scale based on the % 
of immunoreactive neoplastic cells  was:  0–10% = 0; 
10–30% = 1;  30–50% = 2; 50–70% = 3 and 70–100% = 4. 
Sections were also scored on the basis of staining intensity 
as negative = 0; mild = 1; moderate = 2; intense =3. Finally, 
a immunoreactive staining score (IRS) was obtained by 
adding the score of percentage positivity and intensity and 
samples were classified ad negative/weak staining (IRS < 2) 
and moderated/strong staining (IRS ≥ 2).
Validation of the KEAP1 expression and promoter 
hypermethylation in two independent set of 
ccRCC and PRCC tumors (TCGA data analysis)
KEAP1 Methylation and mRNA expression data for 
ccRCCs and PRCCs were downloaded from the “The Cancer 
Genome Atlas” (TCGA) data portal (https://tcga-data.nci.nih.
gov). These data include n = 481 ccRCCs and n = 265 PRCC 
affected patients from two independent platforms: Illumina 
Infinium DNA methylation (HumanMethylation 450 K) and 
Illumina HiSeq gene expression arrays.
Statistical data analysis
All analyses were performed using SAS Release 9.3 
(SAS Institute, Cary, NC). A p value < 0.05 was considered 
for statistical significance.
Patients baseline characteristics were reported as 
mean and standard deviation or median and interquartile 
range and frequencies and percentages for continuous and 
categorical variables, respectively. Baseline comparisons 
were performed using Mann-Whitney U-test or Pearson 
chi-squared test for continuous and categorical variables, 
respectively.
Methylation level comparison between tumors 
and paired normal tissues was performed by using the 
Wilcoxon Signed Rank test. ROC curve analysis was 
performed to assess the diagnostic performances of 
KEAP1 methylation levels. Sensitivity and specificity 
were also reported at the optimal cut-off which maximized 
jointly sensitivity and specificity. 
Correlation between KEAP1 mRNA expression 
(TCGA Illumina HiSeq platform) and the level of KEAP1 
methylation was assessed using Spearman correlation 
coefficient.
Association between IHC and methylation was 
tested using Mc Nemar test.
Proportional hazard Cox regression analysis was 
performed to assess the association between KEAP1 
methylation and overall survival.
For in vitro experiments, group comparisons were 
performed using two-tailed Student’s t-test. 
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